Leptin resistance, characterized by reduced CNS sensitivity and impaired leptin signaling, leads to elevated peripheral leptin levels that may hypothetically promote inflammation and contribute to MS pathogenesis, while simultaneously diminishing leptin’s central responsiveness and neuroprotective effects contribute to AD. This evidence concerns the gene LEP and myeloid sarcoma.